MBA , CCO Promethera Biosciences Group (Belgium) & Managing Director of Promethera Biosciences LLC (USA)
Mark is a biotech leader with over 20 years’ experience in the field and has a record of turning projects into successful products. He has held various senior level positions in several regenerative medicine companies such as Founder and President of ADMET Technologies - a cell based assay company, President of Vesta Therapeutics - a liver stem cell therapy company (acquired by Cytonet in 2009), and President & COO of Cytonet LLC (acquired by Promethera in 2016).
At Promethera, Mark is responsible for all US operations including Organ Procurement Organization management, cell manufacturing according to GMP, commercial manufacturing of Heparesc, managing relationships with KOL’s and patient advocacy groups, as well as starting and managing multiple revenue programs. Mark is a board member of Donate Life North Carolina which has the objective to foster organ donation within the state of North Carolina.
Mark received his MBA from the London Business School, and a BS in the Physical Sciences from the University of Maryland, College Park.